Abstract
Temozolomide, an alkylating agent, has shown promise in treating primary central nervous system lymphoma (PCNSL). The enzyme O6-methylguanine-DNA methyltransferase (MGMT) repairs alkylating damage, such as that induced by temozolomide. We hypothesized that MGMT immunohistochemistry would predict resistance to temozolomide in PCNSL. A retrospective study of newly-diagnosed and recurrent PCNSL patients treated at our institution was conducted to study the predictive value of MGMT immunohistochemistry for response to temozolomide. 20 patients who were treated with temozolomide as a single agent were identified during the study time period. 6/20 patients demonstrated a response, corresponding to an objective response rate of 30 % (95 % CI 8–52). Five patients with low MGMT level (<30 %) showed a response to temozolomide. Only one of 10 patients (10 %) with high MGMT level (≥30 %) exhibited a response to temozolomide. Small sample numbers precluded formal statistical comparisons. Two patients with complete response remain alive without progressive disease 6.7 and 7.2 years after temozolomide initiation. Immunohistochemistry can be performed on small biopsies to selectively assess MGMT status in tumor versus surrounding inflammation. MGMT analysis by immunohistochemistry may predict response to temozolomide in PCNSL and should be prospectively investigated.
Similar content being viewed by others
References
Kadan-Lottick NS, Skluzacek MC, Gurney JG (2002) Decreasing incidence rates of primary central nervous system lymphoma. Cancer 95(1):193–202
Batchelor T, Loeffler JS (2006) Primary CNS lymphoma. J Clin Oncol 24(8):1281–1288. doi:10.1200/jco.2005.04.8819
Harder H, Holtel H, Bromberg JEC, Poortmans P, Haaxma-Reiche H, Kluin-Nelemans HC, Menten J, van den Bent MJ (2004) Cognitive status and quality of life after treatment for primary CNS lymphoma. Neurology 62(4):544–547
Mohile NA, Abrey LE (2007) Primary central nervous system lymphoma. Semin Radiat Oncol 17(3):223–229
Bessell EM, Hoang-Xuan K, Ferreri AJM, Reni M (2007) Primary central nervous system lymphoma—biological aspects and controversies in management. Eur J Cancer 43(7):1141–1152
DeAngelis LM, Iwamoto FM (2006) An update on therapy of primary central nervous system lymphoma. Hematology 1:311–316. doi:10.1182/asheducation-2006.1.311
Doolittle ND, Jahnke K, Belanger R, Ryan DA, Nance RW, Lacy CA, Tyson RM, Haluska M, Hedrick NA, Varallyay C, Neuwelt EA (2007) Potential of chemo-immunotherapy and radioimmunotherapy in relapsed primary central nervous system (CNS) lymphoma. Leuk Lymphoma 48(9):1712–1720
Ferreri AJM, Abrey LE, Blay J-Y, Borisch B, Hochman J, Neuwelt EA, Yahalom J, Zucca E, Cavalli F, Armitage J, Batchelor T (2002) Summary statement on primary central nervous system lymphomas from the eighth international conference on malignant lymphoma, Lugano, Switzerland, June 12 to 15. J Clin Oncol 21(12):2407–2414. doi:10.1200/jco.2003.01.135
Gerstner E, Batchelor T (2007) Primary CNS lymphoma. Expert Rev Anticancer Ther 7(5):689–700. doi:10.1586/14737140.7.5.689
Panageas Katherine S, EBELB-PLMDLEA (2007) Patterns of treatment in older adults with primary central nervous system lymphoma. Cancer 110(6):1338–1344
Fliessbach K, Helmstaedter C, Urbach H, Althaus A, Pels H, Linnebank M, Juergens A, Glasmacher A, Schmidt-Wolf IG, Klockgether T, Schlegel U (2005) Neuropsychological outcome after chemotherapy for primary CNS lymphoma: a prospective study. Neurology 64(7):1184–1188. doi:10.1212/01.wnl.0000156350.49336.e2
Widemann BC, Adamson PC (2006) Understanding and managing methotrexate nephrotoxicity. Oncologist 11(6):694–703. doi:10.1634/theoncologist.11-6-694
Abrey LE, Correa DD (2005) Treatment-Related Neurotoxicity. Hematol Oncol Clin N Am 19(4):729–738
Herrlinger U, Kuker W, Platten M, Dichgans J, Weller M (2002) First-line therapy with temozolomide induces regression of primary CNS lymphoma. Neurology 58(10):1573–1574
Lerro KA, Lacy J (2002) Case report: a patient with primary CNS lymphoma treated with temozolomide to complete response. J Neurooncol 59(2):165–168
Makino K, Nakamura H, Kudo M, Takeshima H, Kuratsu J (2007) Complete response to temozolomide treatment in an elderly patient with recurrent primary central nervous system lymphoma–case report. Neurol Med Chir (Tokyo) 47(5):229–232
Reni M, Zaja F, Mason W, Perry J, Mazza E, Spina M, Bordonaro R, Ilariucci F, Faedi M, Corazzelli G, Manno P, Franceschi E, Pace A, Candela M, Abbadessa A, Stelitano C, Latte G, Ferreri AJ (2007) Temozolomide as salvage treatment in primary brain lymphomas. Br J Cancer 96(6):864–867. doi:10.1038/sj.bjc.6603660
Enting RH, Demopoulos A, DeAngelis LM, Abrey LE (2004) Salvage therapy for primary CNS lymphoma with a combination of rituximab and temozolomide. Neurology 63(5):901–903
Reni M, Mason W, Zaja F, Perry J, Franceschi E, Bernardi D, Dell’Oro S, Stelitano C, Candela M, Abbadessa A, Pace A, Bordonaro R, Latte G, Villa E, Ferreri AJM (2004) Salvage chemotherapy with temozolomide in primary CNS lymphomas: preliminary results of a phase II trial. Eur J Cancer 40(11):1682–1688
Omuro AM, Taillandier L, Chinot O, Carnin C, Barrie M, Hoang-Xuan K (2007) Temozolomide and methotrexate for primary central nervous system lymphoma in the elderly. J Neurooncol 85(2):207–211
Friedman HS, McLendon RE, Kerby T, Dugan M, Bigner SH, Henry AJ, Ashley DM, Krischer J, Lovell S, Rasheed K, Marchev F, Seman AJ, Cokgor I, Rich J, Stewart E, Colvin OM, Provenzale JM, Bigner DD, Haglund MM, Friedman AH, Modrich PL (1998) DNA mismatch repair and O6-alkylguanine-DNA alkyltransferase analysis and response to Temodal in newly diagnosed malignant glioma. J Clin Oncol 16(12):3851–3857
Hegi ME, Diserens A-C, Gorlia T, Hamou M-F, de Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani L, Bromberg JEC, Hau P, Mirimanoff RO, Cairncross JG, Janzer RC, Stupp R (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352(10):997–1003. doi:10.1056/NEJMoa043331
Kurzwelly D, Glas M, Roth P, Weimann E, Lohner H, Waha A, Schabet M, Reifenberger G, Weller M, Herrlinger U (2010) Primary CNS lymphoma in the elderly: temozolomide therapy and MGMT status. J Neurooncol 97(3):389–392. doi:10.1007/s11060-009-0032-0
Makino K, Nakamura H, Hide T-i, Kuratsu J-i (2012) Salvage treatment with temozolomide in refractory or relapsed primary central nervous system lymphoma and assessment of the MGMT status. J Neurooncol 106(1):155–160. doi:10.1007/s11060-011-0652-z
Quinn JRD, Rich J, et al. (2003) Phase II treatment of adults with newly diagnosed, progressive or recurrent primary central nervous system lymphoma with temodar. Paper presented at the ASCO, Chicago, Ill
McLendon RE, Cleveland L, Pegram C, Bigner SH, Bigner DD, Friedman HS (1998) Immunohistochemical detection of the DNA repair enzyme O6-methylguanine-DNA methyltransferase in formalin-fixed, paraffin-embedded astrocytomas. Lab Invest 78(5):643–644
Wong ET, Tishler R, Barron L, Wu JK (2004) Immunochemotherapy with rituximab and temozolomide for central nervous system lymphomas. Cancer 101(1):139–145. doi:10.1002/cncr.20339
Ohno T, Hiraga J, Ohashi H, Sugisaki C, Li E, Asano H, Ito T, Nagai H, Yamashita Y, Mori N, Kinoshita T, Naoe T (2006) Loss of O6-methylguanine-DNA methyltransferase protein expression is a favorable prognostic marker in diffuse large B-cell lymphoma. Int J Hematol 83(4):341–347
Chu LC, CGESAGJGH (2006) Epigenetic silencing of multiple genes in primary CNS lymphoma. Int J Cancer 119(10):2487–2491
Uccella S, Cerutti R, Placidi C, Marchet S, Carnevali I, Bernasconi B, Proserpio I, Pinotti G, Tibiletti MG, Furlan D, Capella C (2009) MGMT methylation in diffuse large B-cell lymphoma: validation of quantitative methylation-specific PCR and comparison with MGMT protein expression. J Clin Pathol 62(8):715–723. doi:10.1136/jcp.2009.064741
Quillien V, Lavenu A, Karayan-Tapon L, Carpentier C, Labussière M, Lesimple T, Chinot O, Wager M, Honnorat J, Saikali S, Fina F, Sanson M, Figarella-Branger D (2012) Comparative assessment of 5 methods (methylation-specific polymerase chain reaction, methylight, pyrosequencing, methylation-sensitive high-resolution melting, and immunohistochemistry) to analyze O6-methylguanine-DNA-methyltranferase in a series of 100 glioblastoma patients. Cancer 118(17):4201–4211. doi:10.1002/cncr.27392
Adachi J-i, Mishima K, Wakiya K, Suzuki T, Fukuoka K, Yanagisawa T, Matsutani M, Sasaki A, Nishikawa R (2012) O6-methylguanine-DNA methyltransferase promoter methylation in 45 primary central nervous system lymphomas: quantitative assessment of methylation and response to temozolomide treatment. J Neuro Oncol 107:147. doi:10.1007/s11060-011-0721-3
Abrey LE, Batchelor TT, Ferreri AJM, Gospodarowicz M, Pulczynski EJ, Zucca E, Smith JR, Korfel A, Soussain C, DeAngelis LM, Neuwelt EA, O’Neill BP, Thiel E, Shenkier T, Graus F, van den Bent M, Seymour JF, Poortmans P, Armitage JO, Cavalli F (2005) Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma. J Clin Oncol 23(22):5034–5043. doi:10.1200/jco.2005.13.524
Mutter N, Stupp R (2006) Temozolomide: a milestone in neuro-oncology and beyond? Expert Rev Anticancer Ther 6(8):1187–1204
Acknowledgments
The authors would like to acknowledge Ms. Debra Fleming and Mrs. Kathryn Perkinson for their technical assistance.
Ethical standards
The described experiments comply with the current laws of the United States.
Conflict of interest
The authors declare that they have no conflict of interest.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Jiang, X., Reardon, D.A., Desjardins, A. et al. O6-methylguanine-DNA methyltransferase (MGMT) immunohistochemistry as a predictor of resistance to temozolomide in primary CNS lymphoma. J Neurooncol 114, 135–140 (2013). https://doi.org/10.1007/s11060-013-1162-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11060-013-1162-y